2023 World Conference on Lung Cancer (Posters)-EP11.01. Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study

EP11.01. Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study - PDF(Slides)

Back to course

Pdf Summary

A study conducted in Italy examined the use of first-line chemo-immunotherapy in patients with advanced lung adenocarcinoma. The treatment consisted of pembrolizumab combined with platinum-pemetrexed chemotherapy. The study aimed to evaluate the clinical outcomes and safety of this treatment regimen.<br /><br />The study included 1068 patients who received the treatment in 36 Italian centers. The median follow-up was 17.0 months. The results showed that the overall survival of the patients was 16.1 months, which is similar to the findings of a previous registration study. The median progression-free survival was 9.9 months and the overall response rate was 43.4%.<br /><br />Subgroup analysis indicated that age, sex, smoking status, and PD-L1 status did not significantly impact the outcomes. However, factors such as Eastern Cooperative Oncology Group Performance Status, the presence of brain metastases, the number of metastatic sites, and steroid use at treatment start had significant effects on the outcomes.<br /><br />The study demonstrated that the treatment regimen was effective and safe in a real-world setting. It emphasized the importance of considering individual patient characteristics when making treatment decisions. The most common treatment-related adverse events were hematologic, gastrointestinal, cutaneous, and hepatic.<br /><br />Overall, the study adds to the growing evidence supporting the use of chemo-immunotherapy as a first-line treatment for advanced lung adenocarcinoma. Further research is needed to validate these findings and explore other factors that may influence treatment outcomes.

Asset Subtitle

Alessandro Leonetti

Meta Tag

Speaker Alessandro Leonetti

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

Italy

first-line chemo-immunotherapy

advanced lung adenocarcinoma

pembrolizumab

platinum-pemetrexed chemotherapy

clinical outcomes

safety

overall survival

progression-free survival

overall response rate